iRadimed Corporation (NASDAQ:IRMD) Stock Rated “Moderate Buy” by Sell-Side Analysts

Shares of iRadimed Corporation (NASDAQ:IRMD) have earned a consensus recommendation of “Moderate Buy” from the six research firms that are presently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $120.00.

Several research firms recently commented on IRMD. Needham & Company LLC started coverage on iRadimed in a research report on Tuesday, September 22nd. They issued a “hold” rating on the stock. Wall Street Zen lowered iRadimed from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, Weiss Ratings raised iRadimed from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Friday, October 16th.

iRadimed Trading Down 0.0%

NASDAQ:IRMD opened at $83.93 on Friday. iRadimed has a 52 week low of $75.75 and a 52 week high of $107.90. The stock has a 50 day moving average of $85.89 and a 200-day moving average of $92.86. The firm has a market capitalization of $1.07 billion, a PE ratio of 46.89 and a beta of 0.91.

iRadimed (NASDAQ:IRMD) last posted its earnings results on Friday, July 31st. The medical equipment provider reported $0.46 EPS for the quarter, topping the consensus estimate of $0.44 by $0.02. iRadimed had a net margin of 26.70% and a return on equity of 23.45%. The firm had revenue of $20.47 million during the quarter, compared to analysts’ expectations of $20.35 million. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. As a group, analysts predict that iRadimed will post 1.98 EPS for the current fiscal year.

Insider Buying and Selling at iRadimed

In related news, Director Monty K. Allen sold 1,419 shares of the company’s stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $86.41, for a total value of $122,615.79. Following the completion of the sale, the director owned 19,581 shares of the company’s stock, valued at $1,691,994.21. This represents a 6.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 34.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On iRadimed

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Inspire Investing LLC lifted its holdings in shares of iRadimed by 13.1% during the 3rd quarter. Inspire Investing LLC now owns 1,421 shares of the medical equipment provider’s stock valued at $123,000 after buying an additional 165 shares during the last quarter. Kings Path Partners LLC acquired a new position in iRadimed in the third quarter worth approximately $590,000. Nisa Investment Advisors LLC increased its holdings in iRadimed by 49.6% in the third quarter. Nisa Investment Advisors LLC now owns 1,643 shares of the medical equipment provider’s stock worth $142,000 after buying an additional 545 shares during the last quarter. IFP Advisors Inc increased its holdings in iRadimed by 308.4% in the third quarter. IFP Advisors Inc now owns 2,324 shares of the medical equipment provider’s stock worth $200,000 after buying an additional 1,755 shares during the last quarter. Finally, Davidson Capital Management Inc. increased its holdings in iRadimed by 11.2% in the third quarter. Davidson Capital Management Inc. now owns 63,017 shares of the medical equipment provider’s stock worth $5,433,000 after buying an additional 6,333 shares during the last quarter. Institutional investors own 92.34% of the company’s stock.

iRadimed Company Profile

iRadimed Corporation (NASDAQ: IRMD) develops, manufactures and sells medical devices designed for use during magnetic resonance imaging (MRI) procedures. The company focuses on solutions that allow clinicians to deliver intravenous medications and monitor patients safely while they are in or near an MRI scanner.

Its principal products include the MRidium MRI-compatible infusion pump systems, which are designed to administer intravenous fluids and medications without interfering with MRI operations.